Investigation Launched into Pharming Group Following Major Revenue Decline in Q2 2026

Investigation into Pharming Group's Decline

Pharming Group (PHAR), renowned for its product RUCONEST, has recently found itself under the microscope following a substantial drop in revenue for the second quarter of 2026. The company reported revenues of $72.3 million, marking a 10% decline compared to the same period last year. This downturn triggered a sharp 22% fall in PHAR's stock on the day the results were announced, startling many investors who may have felt blindsided by the outcome.

Recent Financial Performance

During the earnings call held on November 6, 2025, CEO Fabrice Chouraqui acknowledged the competition posed by sebetralstat and expressed uncertainty about RUCONEST's positioning. As time has progressed, it appears that this candidness may not have adequately prepared investors for the ongoing challenges faced by RUCONEST. While newer treatments like Joenja have shown remarkable growth—recording a 40% increase to $17.9 million—the overall decline in traditional offerings has dampened the company’s total revenue, which fell to $90.2 million, a 3% decrease year-on-year. Investors are left wondering if there were prior indications of these drops that went unaddressed.

Investigative Action

In light of these troubling financial results, Levi & Korsinsky, a prominent securities firm, is spearheading an investigation into Pharming Group. The main focus is whether the company adequately disclosed the competitive pressures affecting RUCONEST and its broader financial outlook. Investors who have suffered losses are encouraged to come forward and share their stories. This investigation is crucial—examining if any misleading statements were made that could have impacted investors’ decisions during this tumultuous period.

Questions Facing the Company

Key inquiries include the nature of statements made by Pharming regarding their RUCONEST sales and whether those statements reflected true market conditions. Chief among them is the question of how much investors were misinformed about the potential impacts of competitive therapies on the company's revenue streams.

Investors looking to participate in the investigation must gather evidence of their investments in Pharming Group, including purchase dates and the amount of shares acquired. Notably, eligibility is determined based on documented financial losses rather than whether they still hold shares. Moreover, it doesn't come with upfront costs, as any resulting actions from the investigation typically proceed on a contingency basis. This means there are no retainers or out-of-pocket costs for participants.

Next Steps for Investors

For those affected, the investigation by Levi & Korsinsky offers a critical opportunity to pursue justice. Investors should act promptly and engage with the firm's legal team for an evaluation of their losses—assisting them in understanding their options without the fear of incurring costs. Those affected can contact the firm via the provided email or telephone for a free assessment.

As Pharming Group navigates these challenges, shareholders are left in a state of uncertainty, pondering the future of their investments in light of these recent developments and the proactive measures being taken by their legal representatives. Their fate—alongside the enduring legacy of RUCONEST—rests on the outcomes of this investigation and the responses from Pharming's leadership.

In today’s fast-paced healthcare market, transparency is critical, and the pressure is on Pharming Group. This investigation marks just the beginning of what could be a pivotal moment for the company and its valued shareholders.